Secondly, we determined the expression of 68 immune checkpoint-related genes in IMvigor210 and BLCA cohorts, which were screened from the literature20, and found that the SRPI risk score was negatively correlated with most of these genes, including PD-1, PD-L1, CTLA4, CD80, CD86, LAG3, CD96, CD226, and TIGIT (Supplementary Figs. 5a and 6a). The gene discussed is CD226; the disease is bladder transitional cell carcinoma.